Epilepsy Drugs Market
The study for Global Epilepsy Drugs Market Survey and Trend Research 2017 will provide market size, estimates and forecast based on the following years:
Historic data: 2015-16 Base Year Estimate: 2017 Forecast: 2017 to 2025
The report has been categorized in two distinctive sections, where the first category titled as Market Overview provides a holistic view of the market, key trends, drivers, challenges/restraints or opportunities with their current and expected impact on the overall industry sales.
Our analyst implement, several qualitative tools such as Ansoff’s Matrix, PESTEL analysis, Porter’s five force analysis among other to interpret and represent key industry findings.
The second section of the study provides market size, estimates and forecast for key market segments and regional market. The final part of the report highlights key manufacturers/vendors operating in the associated market.
Historic data: 2015-16 Base Year Estimate: 2017 Forecast: 2017 to 2025
The report has been categorized in two distinctive sections, where the first category titled as Market Overview provides a holistic view of the market, key trends, drivers, challenges/restraints or opportunities with their current and expected impact on the overall industry sales.
Our analyst implement, several qualitative tools such as Ansoff’s Matrix, PESTEL analysis, Porter’s five force analysis among other to interpret and represent key industry findings.
The second section of the study provides market size, estimates and forecast for key market segments and regional market. The final part of the report highlights key manufacturers/vendors operating in the associated market.
By performing electroencephalogram (EEG), Epilepsy can be confirmed. Looking for abnormal patterns of brain waves and neuroimaging (CT scan or MRI) and then at the structure of the brain.
Once a second seizure has occurred, Epilepsy is treated with daily medication generally. The Anti-epileptic drugs (AEDs) are generally taken orally. The drug is prescribed by the Doctor, seeing the type of seizure. Although patients do not react to the drugs in the same way, AEDs appear to help control seizures in 70 % of the cases.
Once a second seizure has occurred, Epilepsy is treated with daily medication generally. The Anti-epileptic drugs (AEDs) are generally taken orally. The drug is prescribed by the Doctor, seeing the type of seizure. Although patients do not react to the drugs in the same way, AEDs appear to help control seizures in 70 % of the cases.
Patients with epilepsy are 11 times more likely to experience premature death in comparison with others.
Human brain is the source of epilepsy. Epilepsy is one of the most common neurological diseases, as per the World Health Organization (WHO); nearly 50 million people have epilepsy worldwide.
Due to huge patient base and increasing incidences of neurological disorders, these factors will fuel the growth of Epilepsy Drugs market.
Due to huge patient base and increasing incidences of neurological disorders, these factors will fuel the growth of Epilepsy Drugs market.
Segmentation:
The Epilepsy Drugs market is segmented on the basis of generation of drugs, spectrum of activity, seizure type and region.
On the basis of generation of drugs, the market is segmented into first-generation, second-generation and third-generation.
On the basis of spectrum of activity, the market is segmented into narrow-spectrum and broad-spectrum.
On the basis of seizure type, the market is segmented into partial onset seizures and generalized seizures.
The Epilepsy Drugs market is segmented on the basis of generation of drugs, spectrum of activity, seizure type and region.
On the basis of generation of drugs, the market is segmented into first-generation, second-generation and third-generation.
On the basis of spectrum of activity, the market is segmented into narrow-spectrum and broad-spectrum.
On the basis of seizure type, the market is segmented into partial onset seizures and generalized seizures.
Regional Analysis:
Geographically, the Epilepsy Drugs market is segregated in North America, Europe, Asia Pacific, and LAMEA (Latin America, Middle East and Africa).
Geographically, the Epilepsy Drugs market is segregated in North America, Europe, Asia Pacific, and LAMEA (Latin America, Middle East and Africa).
Key Players:
The major key players in Epilepsy Drugs market are: Abbott Laboratories, Cephalon, Inc., Eisai Co., Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Pfizer, Inc., Sanofi S.A., Sunovion Pharmaceuticals, Inc., UCB Pharma Ltd., Valeant pharmaceuticals International, Inc.
Segmentation:-
By Generation of Drugs
• First-generation
• Second-generation
• Third-generation
• First-generation
• Second-generation
• Third-generation
By Spectrum of Activity
• Narrow-spectrum
• Broad-spectrum
• Narrow-spectrum
• Broad-spectrum
By Seizure Type
• Partial onset seizures
• Generalized seizures
• Partial onset seizures
• Generalized seizures
By Geography:
• North America
• Europe
• Asia-Pacific
• LAMEA
• North America
• Europe
• Asia-Pacific
• LAMEA
We at Garner Insights.com provide a comprehensive analysis by providing in-depth reports of the
various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide
backed by rich data. Decision makers can now rely on our well-defined data gathering methods to
get the correct and accurate market forecasting along with detailed analysis.
Contact Us:-
Kevin Thomas
Direct:
+1 513 549 5911 (US)
+44 203 318 2846 (UK)
Email: sales@garnerinsights.com
No comments:
Post a Comment